[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-heart-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-heart-failure":654},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,43,0,25,[9,47,78,101,128,147,169,195,219,246,266,290,313,350,370,393,426,446,471,499,522,541,571,601,625],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100533152",false,"NCT06222099","The HEARTFELT Study","A Pragmatic, Single-blind, Randomized Crossover Trial Testing the Effectiveness of Autonomous Remote Patient Peripheral Edema Monitoring and Reporting in HEART FailurE Compared to conventionaL remoTe Patient Monitoring.","HEARTFELT","INCLUSION CRITERIA:\n\n1. Provision of signed and dated informed consent form (wet or digital signature)\n2. Male or female, aged 22 to \\[No maximum age\\]\n3. Diagnosed with Chronic Heart failure at least 2 months prior to randomization\n4. Documented history of peripheral edema (edema in feet and lower legs), defined as at least one clinical mention in the medical record indicative of oedema during prior clinical assessment.\n5. Evidence of heart failure decompensation or elevated risk of future hospitalization, defined by one or more of the following:\n\n   a.Hospitalization for heart failure occurring at least once in the past 6 months or at least twice in the past 12 months; OR b.Receipt of intravenous\u002Fsubcutaneous diuretic therapy for heart failure (inpatient or outpatient setting) occurring at least once in the past 6 months or at least twice in the past 12 months; OR c.Emergency department or urgent care visit for heart failure decompensation, occurring at least once in the past 6 months or at least twice in the past 12 months; OR d.Clinician assessment that the participant is at high risk of heart failure hospitalization within the next 6-12 months, based on documented recent clinical course (e.g. worsening congestion, escalating diuretic requirements, recurrent decompensation, and\u002For comorbidity burden).\n6. Patients who are treated with daily diuretics.\n7. Evidence of non-adherence defined by one or more of the following:\n\n   1. Participants with ≥180 days of historical monitoring\u002Fdevice data available\n\n      ● Failure to collect ≥50% of expected days of prescribed home physiological monitoring data (e.g. weight, blood pressure, or other clinician-recommended measurements), assessed over a continuous 180-day period; OR\n\n      ● Discontinuation from a remote patient monitoring\u002Fhome monitoring program due to non-adherence; OR\n\n      ● Failure to adhere to a prescribed home-based therapy\u002Fmonitoring intervention, supported by device usage data showing \\\u003C50% of expected days of use over a continuous 180-day period.\n   2. Participants without ≥180 days of historical monitoring\u002Fdevice data available: Evidence of non-adherence may be demonstrated by low data capture over shorter windows, defined as any of the following :\n\n      ● ≤2 days of monitoring data recorded for each of the most recent 4 consecutive weeks during which any remote monitoring device was continuously available in the patient's home; OR\n\n      ● ≤3 days of monitoring data recorded in any consecutive 8 week period period during which any remote monitoring device was continuously available in the patient home; AND\u002FOR\n      * by documented non-adherence in the medical record within the last 3 years:\n\n        * Historical documentation of persistent medication and\u002For dietary non-adherence, defined as either a clear statement of ongoing non-adherence or ≥2 documented instances of non-adherence concerns (including dosing and\u002For timing, where available); OR\n        * Historical documentation on repeated clinical assessments indicating persistent difficulty adhering to recommended self-management activities (e.g. repeated failure to follow monitoring instructions, incomplete engagement with care plan, or repeated non-attendance at scheduled reviews).\n   3. For participants not previously enrolled in RPM or without sufficient historical monitoring data, non-adherence will be assessed prospectively using connected scales provided at study initiation. Objective adherence metrics derived from scale usage during the initial monitoring period will be used both to characterise baseline adherence and to support predefined subgroup analyses.\n   4. Clinical teams\u002FPIs discretion as patients being non-adherent.\n8. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 6 weeks after the end of the study.\n9. Patients who are covered by an insurance plan that covers IDE-B costs (e.g. Medicare Part-B), OR written contract signed by the patient, or their provider or payor, stating that they will be liable for any trial-associated costs that Medicare would ordinarily cover if the patient were covered by Medicare.\n\n1\\. Participant has bandages to lower limbs every day 2. Participant has an amputation of both feet 3. Participant is a regular wheelchair user inside their home 4. Participant is bed-bound 5. Participant is of no fixed abode 6. Participant is taking part in a conflicting evaluation\u002Fstudy that could confound the results of this evaluation and\u002For impact clinical interventions and participant outcomes 7. Participant is unable to take diuretics 8. Participant is on a regular schedule of dialysis 9. Participant has a history of recurrent leg or feet deep vein thrombosis (DVT) (two or more episodes within the last 12 months).\n\n10\\. Participant has a history of recurrent leg or feet cellulitis episodes (two or more episodes within the last 12 months).\n\n11\\. Participant is prescribed diltiazem or verapamil on an ongoing basis. 12. Participant is pregnant or is not taking medically approved birth control if of child-bearing potential.","ALL","22 Years",{"count":20,"type":21},1500,"ESTIMATED","INTERVENTIONAL",[24],"NA","This pragmatic randomized crossover trial looks at the effect(s) of using a remote patient monitoring device (Heartfelt device) with health alerts to monitor the development of peripheral edema in patients with heart failure (HF). The hypothesis is that this passive measurement method will lead to better data availability, which in turn will improve patient care and reduce hospitalizations for the management of worsening HF (HF hospitalizations, HFHs) in nonadherent participants with chronic HF. The study objectives are:\n\n* Primary objective: Establish if the Heartfelt device is safe to use and effective at reducing HFHs.\n* Secondary objectives:\n\n  1. Establish the effect of the Heartfelt device on data availability compared to existing remote monitoring devices.\n  2. Establish the effect of the Heartfelt device on HF clinical outcomes.\n\nParticipants will need to:\n\n* Install the device in their home for at least a year and up to 4 additional years after.\n* Reply to remote patient monitoring phone calls to follow the care plans.",[27,28],"Heart Failure","Chronic Heart Failure",[30,31,32,33],"remote patient monitoring","chronic heart failure","heart failure","non-adherent heart failure","RECRUITING","2026-06-26",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":38},"2025-10-23",{"date":42,"type":21},"2030-12-31",{"name":44,"class":45},"Heartfelt Technologies","INDUSTRY",3,{"id":48,"slug":4,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100500264","NCT05793996","The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF)","Study of the Prevalence of Iron Deficiency Among Hospitalized Patients With HFpEF and the Impact of Ferinject® on Indicators of Quality of Life, Functional Status in Patients With Iron Deficiency","ID-HFpEF","Inclusion Criteria:\n\n* Signed informed consent to participate in the study;\n* In New York Heart Association (NYHA) II-III functional class due to stable symptomatic chronic heart failure (CHF);\n* Left ventricular ejection fraction (LVEF) ≥50%; objective signs of structural and\u002For functional disorders of the heart consistent with the presence of LV diastolic dysfunction\u002Fincreased LV filling pressure, including elevated levels of natriuretic peptide;\n* Screening ferritin below 100 µg\u002FL, or below 300 µg\u002FL when transferrin saturation (TSAT) is below 20%;\n* Screening haemoglobin (Hb) at the time of switching on ( 90-150 g\u002Fl).\n\nExclusion Criteria:\n\n* Uncontrolled arterial hypertension;\n* Аnemia not related to iron deficiency;\n* Аnemia with a hemoglobin level of less than 90 g\u002Fl;\n* Less than 1 year after acute myocardial infarction;\n* Less than 1 year after acute cerebral circulation disorder;\n* Less than 1 year after surgical interventions, including non-cardiac operations and myocardial revascularization (coronary bypass surgery, coronary artery stenting), operations for valvular pathology;\n* Chronic alcoholism (including alcoholic heart disease), mental disorders;\n* Severe hepatic (increased transaminase levels above the upper three limits of normal) and renal insufficiency (glomerular filtration rate less than 15 ml\u002Fmin\u002F1.73 m2);\n* Known active infection, clinically significant bleeding, active malignancy;\n* Severe autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, etc.);\n* Severe bronchial asthma, COPD in the acute stage;\n* Allergic reactions to medications in the anamnesis, eczema, atopic allergic reaction;\n* Blood transfusions and taking erythropoiesis-stimulating drugs during the previous three months.","18 Years",{"count":56,"type":21},100,[58],"PHASE4","Observational cohort randomized controlled study to study the influence of correction of ID by intravenous injection of ferric carboxymaltose (Ferinject®) on quality of life indicators, functional status in a cohort of patients with HFpEF.",[28,61],"Iron Deficiency, Latent",[63,64,65,66],"HFpEF","iron deficiency","ferric carboxymaltose","Ferinject","2026-06-23",{"date":69,"type":38},"2026-06-24",{"date":71,"type":38},"2023-04-28",{"date":73,"type":21},"2026-12",{"name":75,"class":76},"Tomsk National Research Medical Center of the Russian Academy of Sciences","OTHER",1,{"id":79,"slug":4,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":77},"100548638","NCT06423599","Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure","FIT-HF","Inclusion Criteria:\n\n* Male or female, age ≥ 18 years at the time of signing informed consent\n* Body mass index (BMI) ≥ 30 kg\u002Fm2\n* Heart failure with New York Heart Association (NYHA)-class 1-3 and reduced ejection fraction (EF≤40%) established by either:\n\n  1. echocardiography AND\u002FOR\n  2. cardiac magnetic resonance\n* On stable optimal medical heart failure therapy for at least 4 weeks\n\nExclusion Criteria:\n\n1. Cardiovascular-related:\n\n   * Any of the following: myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within the past 6 months prior to the day of screening\n   * Planned coronary, carotid or peripheral artery revascularisation known on the day of screening\n   * Transient heart failure related to reversible mechanisms like tachycardia, sepsis, etc.\n2. Glycaemia-related:\n\n   * Type 1 diabetes\n   * Treatment with any Glucagon-Like Peptide-1 (GLP-1) agonists within 90 days prior to the day of screening\n   * Type 2 diabetes requiring other pharmacotherapy than metformin and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors\n3. General safety:\n\n   * Pregnancy or planned pregnancy\n   * History or presence of chronic pancreatitis\n   * Presence of acute pancreatitis within the past 180 days prior to the day of screening\n   * Kidney disease with eGFR \\\u003C 35ml\u002Fmin\n   * Presence or history of malignant neoplasms within the past 5 years prior to the day of screening (Basal and squamous cell skin cancer and any carcinoma in-situ are allowed)\n   * Known or suspected hypersensitivity to trial product(s) or related products",{"count":56,"type":21},[86,87],"PHASE2","PHASE3","The benefit of weight loss in patients with obesity and heart failure with reduced ejection fraction (HFrEF) is controversial. Semaglutide has shown cardiovascular (CV) risk-reduction and impact on CV risk factors including overweight, dysglycaemia and hypertension in subjects with type 2 diabetes (T2D). The STEP-HFpEF (Semaglutide Treatment Effect in People With Obesity and HFpEF) recently demonstrated, at 1-year, to not only reduce weight considerably, but also significantly improve health-related quality of life, functional status scores and 6-min walk distance in patients with heart failure with preserved ejection fraction (HFpEF). Also, the recently concluded SELECT trial was the first CV outcome trial with semaglutide in patients with overweight or obesity and established CV disease, including heart failure (but no T2D). Semaglutide demonstrated a 20% reduction in MACE, defined as the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.\n\nThese landmark findings have important implications for clinicians -as they mean that weight loss and\u002For semaglutide as anti-obesity pharmacotherapy could be a treatment strategy for secondary prevention of CV disease in patients with overweight or obesity.\n\nIt is, however, unknown whether weight loss with either calorie-restricted diet or semaglutide has beneficial effects in obese subjects with heart failure and reduced ejection fraction. Also it is unclear whether semaglutide has cardiovascular benefits irrespective of starting weight and amount of weight loss.\n\nPurpose: The study aims to investigate whether weight loss treatment with semaglutide is superior to weight loss with calorie-restricted diet in improving peak oxygen uptake in patients with obesity and heart failure with reduced ejection fraction.",[90,91,92,28],"Heart Failure With Reduced Ejection Fraction","Obesity","Weight Loss","2026-06-22",{"date":67,"type":38},{"date":96,"type":38},"2024-04-30",{"date":98,"type":21},"2027-12-30",{"name":100,"class":76},"Jens D Hove, MD,PHD",{"id":102,"slug":4,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":77},"100642287","NCT07650474","Mobile-Based Telemedicine and Health-Related Quality of Life Among Patients With Chronic Heart Failure (MOBILE-HF)","Effectiveness of Mobile-Based Telemedicine on Health-Related Quality of Life Among Patients With Chronic Heart Failure: Protocol for a Quasi-Experimental Study","MOBILE-HF","Inclusion Criteria:\n\n* Adults aged 18-65 years who will be diagnosed with CHF (NYHA class II⁃III)\n* Patients with reduced left ventricular ejection fraction LVEF ≤ 40%\n* Patient who will have access to a mobile phone and will be able to use it\n* Patients who will be able to communicate in Amharic, Oromic, or English\n* Patients who will provide written informed consent\n* Patients who will be diagnosed with HF lasting ≥ 6 months, to be confirmed by echocardiography and clinical assessment\n* Patients with no contraindications for mild to moderate physical activity\n\nExclusion Criteria:\n\n* Patients with NYHA class IV or who will require intensive care at enrollment\n* Patients with other severe medical conditions (e.g., end-stage renal disease, \\& end stage liver disease)\n* Patients with severe cognitive impairment or psychiatric illness that will interfere with participation\n* Patients already enrolled in another telemedicine or intervention study\n* Pregnant and lactating women","65 Years",{"count":110,"type":21},72,[24],"Chronic heart failure (CHF) is a long-term condition in which the heart is unable to pump blood effectively. It can cause symptoms such as shortness of breath, fatigue, swelling in the legs, and reduced ability to perform daily activities. These problems often reduce a patient's quality of life and may lead to frequent hospital visits.\n\nThis study will assess whether a mobile-based telemedicine program can improve the health-related quality of life of patients with chronic heart failure in Ethiopia.\n\nIn this study, 70 adult patients with chronic heart failure will be included. They will be divided into two groups: 35 patients will receive routine care plus mobile-based telemedicine support, and 35 patients will receive routine care only.\n\nThe mobile-based telemedicine program will include health education, medication reminders, lifestyle advice, and follow-up support delivered through phone calls and text messages over an 8-week period.\n\nPatients' quality of life will be measured at the beginning of the study and again after 8 weeks using a standard questionnaire called the Minnesota Living with Heart Failure Questionnaire (MLHFQ).\n\nThe main goal of the study is to determine whether mobile-based telemedicine improves quality of life compared with routine care alone. The study may also help improve self-care behaviors, medication adherence, and symptom control among patients with heart failure.\n\nThe findings may provide evidence to support the use of mobile health technologies as a simple and scalable approach to improve heart failure care in Ethiopia.",[28,114],"Health Related Quality of Life",[116,117,118],"Health-related quality of life","Mobile-based telemedicine","Chronic heart failure","2026-06-15",{"date":121,"type":38},"2026-06-17",{"date":123,"type":38},"2026-03-02",{"date":125,"type":21},"2026-08-21",{"name":127,"class":76},"Select College",{"id":129,"slug":4,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":77},"100490468","NCT05666518","A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions","Vericiguat Drug Use Two-arm Investigation in Chronic Heart Failure","Inclusion Criteria:\n\nvericiguat arm:\n\n* Patients receiving standard treatment for chronic heart failure, and vericiguat will be treated in accordance with the package insert (no history of receiving vericiguat)\n* Patients who gave written consent to this investigation\n\ncontrol arm:\n\n* Patients receiving standard treatment for chronic heart failure according to the package insert of vericiguat as following (no history of receiving vericiguat)\n\n  * Prior (within 6 months) heart failure hospitalization or prior (within 3 months) intravenous (IV) diuretics for heart failure not requiring hospitalization (This will be applied only for the first \\~75% of patients meeting this criteria to be enrolled.) Note: No more than approximately 25% of patients without a qualifying history of prior heart failure hospitalization within 6 months or prior IV diuretics for heart failure not requiring hospitalization within 3 months can be enrolled in the study.\n  * New York Heart Association (NYHA) Classification: Class II to Class IV\n  * Left ventricular ejection fraction (LVEF): less than 45%\n* Patients who gave written informed consent to this study\n\nExclusion Criteria:\n\nvericiguat arm:\n\n\\- Patients who are participating in an interventional study\n\ncontrol arm:\n\n* Patients who have started or are scheduled to start therapy with vericiguat for chronic heart failure\n* Patients who are participating in an interventional study",{"count":135,"type":21},1400,"OBSERVATIONAL","This is an observational study in which data from Japanese people with chronic heart failure who will be receiving vericiguat is studied.\n\nChronic heart failure (HF) is a long-term condition where the heart does not pump blood as well as it should. Heart failure can lead to other serious medical conditions, and it can lead to hospitalization or death.\n\nThe drug vericiguat works by increasing the activity of an enzyme called soluble guanylate cyclase (sGC). The sGC enzyme helps regulate the heart and blood circulation. Vericiguat is already available and approved for doctors to prescribe to people who have heart failure. A limited number of patients have been treated with vericiguat. Therefore information about its safety in a broader population and especially among Japanese people as well as for prolonged periods of treatment is still missing.\n\nIn this study, the researchers want to learn more about how safe vericiguat is if used in Japanese people with long term HF. To see how safe vericiguat is, the researchers will collect the medical problems the participants have during the treatment with vericiguat under real-word conditions. They will particularly focus on the following:\n\n* high blood pressure\n* any medical problems due to combination of the study treatment vericiguat with nitrates and nitric oxide (NO) donors or with PDE5 inhibitors\n* medical problems in participants with liver problems or with reduced kidney function\n* medical problems in participants with low blood pressure below \\\u003C100 mmHg or with symptoms due to low blood pressure\n* any medical problems after prolonged periods of treatment with vericiguat. These medical problems are also known as \"adverse events\" (AEs) which may or may not be related to the study treatment.\n\nIn addition, this study will gather information about how long vericiguat treatment can prevent death caused by cardiovascular problems such as heart attack and stroke compared to standard of care. Cardiovascular death (safety specification) will be assessed in a comparative manner with the control arm as the primary objective\n\nThe participants will receive their treatments as prescribed by their doctors according to the approved product information. The data for this study will be collected using an electronic case report form (eCRF) and medical records. The following data from the study participants will be documented during visits that take place in routine practice:\n\n* underlying and concomitant diseases,\n* prior medication,\n* treatment duration,\n* laboratory parameters,\n* vital signs,\n* results of cardiac exams (e.g. cardiac ultrasound),\n* heart failure related hospitalization events,\n* adverse events. The data collection will start from the beginning of vericiguat\u002Fstandard of care treatment and will cover a time period of 2 years unless no further information can be expected from the participant at a given point in time, or death.\n\nThe total study duration will be six years, including data analysis and cleaning.",[28],"2026-06-12",{"date":119,"type":38},{"date":142,"type":38},"2022-08-31",{"date":144,"type":21},"2028-12-31",{"name":146,"class":45},"Bayer",{"id":148,"slug":4,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":154,"targetDuration":156,"studyType":136,"phases":4,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":4},"100642643","NCT07647848","Therapy Adjustment and IndividuaLized Response With Biomarker Observation in ReaL-world Heart Failure","Therapy Adjustment and IndividuaLized Response With Biomarker Observation in ReaL-world Heart Failure (TAILOR-HF)","TAILOR-HF","Inclusion Criteria:\n\n1. Provide written and dated informed consent for participation prior to trial admission,\n2. Age ≥18 years, female or male\n3. A clinical diagnosis of new onset or worsening of heart failure with a left-ventricular ejection fraction of \\\u003C50%\n4. On treatment with oral or i.v. furosemide ≥40 mg\u002Fday or equivalent (bumetanide 1mg, torasemide 10mg)\n5. Receiving \\\u003C50% of the target doses of at least one of the guidelines recommended pharmacological therapies (clear intolerance not considered)\n6. Anticipated or planned uptitration\n\nExclusion Criteria:\n\n1. Scheduled or on renal replacement therapy,\n2. Clearly documented intolerance to two or more of the following groups of drugs: BB, ARNI, SGLT2i or MRAs.\n3. Diagnosis of peripartum cardiomyopathy, chemotherapy induced cardiomyopathy, current viral myocarditis, right heart failure in absence of left-sided structural disease, pericardial constriction, genetic hypertrophic cardiomyopathy, or infiltrative cardiomyopathy including amyloidosis.\n4. The presence of a mechanical assist device,\n5. Scheduled for mechanical assist device or heart transplant,\n6. Current angina pectoris ≥class III,\n7. Requiring valvular surgery or revascularization in the upcoming 3 months or Coronary Artery Bypass Grafting (CABG) within the past 3 months,\n8. Anticipated need for surgery or any other cardiovascular intervention, except implantable cardioverter defibrillator and\u002For cardiac resynchronization therapy, within 4 weeks,\n9. Other non-cardiac conditions with limited life expectancy (≤ duration of the trial\u002F 1 year),\n10. Participation in another clinical trial apart from non-interventional studies.\n11. Patients with an unscheduled hospital visit or admission for reasons that are not primarily related to worsening of heart failure. Therefore, patients with concomitant pulmonary disease, even if severe, valvular disease, acute coronary syndrome or stroke, may be included when the primary diagnosis for admission to hospital or outpatient clinic visit has been heart failure, rather than the concomitant condition.\n12. Women who are pregnant, breastfeeding or those considering becoming pregnant\n13. Subjects unable to provide informed consent.",{"count":155,"type":21},600,"6 Months","The goal of TAILOR-HF is to integrate clinical data, laboratory parameters, treatment patterns, and circulating biomarkers to identify factors that predict individual response to pharmacological treatment in patients with heart failure.\n\nTAILOR-HF is an observational study with protocol-mandated assessments scheduled at baseline and at 1, 3, and 6 months after enrolment. Additional follow-up data will be collected through telephone visits every 6 months until the last participant has completed the protocol-mandated 6-month visit.",[28,159],"Acute Decompensated Heart Failure","NOT_YET_RECRUITING","2026-06-09",{"date":119,"type":38},{"date":164,"type":21},"2026-09-01",{"date":166,"type":21},"2028-09-01",{"name":168,"class":76},"Maastricht University Medical Center",{"id":170,"slug":4,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":175,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":193,"locationsCount":77},"100640050","NCT07628777","Fecal Microbiota Transplantation for Elderly Patients With HFpEF: A Randomized Controlled Trial","Fecal Microbiota Transplantation for Elderly Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Controlled Trial","Inclusion Criteria:\n\n* 1.Aged ≥ 60 years old;\n* 2.Meeting the diagnostic criteria for HFpEF:\n\n  1. Consistent with the epidemiological and demographic characteristics of HFpEF patients;\n  2. Presence of clinical symptoms and\u002For signs of heart failure;\n  3. Cardiac imaging examination indicating LVEF ≥ 50%;\n  4. In sinus rhythm: BNP ≥ 35 pg\u002Fml and\u002For NT-proBNP ≥ 125 pg\u002Fml;In atrial fibrillation: BNP ≥ 105 pg\u002Fml and\u002For NT-proBNP ≥ 365 pg\u002Fml;\n  5. Meet at least one of the following conditions:\n\n     1. LVMI ≥ 115 g\u002Fm² (male) or ≥ 95 g\u002Fm² (female);\n     2. LAVI \\> 34 ml\u002Fm²;\n     3. Relative wall thickness \\> 0.42, or left ventricular free wall thickness \\> 12 mm;\n     4. Septal e' \\\u003C 7 cm\u002Fs, or lateral e' \\\u003C 10 cm\u002Fs, or average E\u002Fe' ≥ 14;\n     5. Tricuspid regurgitation velocity \\> 2.8 m\u002Fs, or pulmonary artery systolic pressure \\> 35 mmHg;\n* 3.NYHA functional class Ⅱ-Ⅲ;\n* 4.Complicated with metabolic diseases such as hypertension, diabetes and obesity;\n* 5.Accompanied by gastrointestinal symptoms;\n* 6.Well-tolerated to current anti-heart failure regimens with stable medication for at least 1 month;\n* 7.Stable heart failure condition without acute exacerbation;\n* 8.Basically normal cognitive function, capable of understanding scale assessment contents;\n* 9.Able to perform daily activities independently;\n* 10.Fully understanding the purpose of this clinical trial, voluntary participation and signing of written informed consent.\n\nExclusion Criteria:\n\n* 1.Symptoms caused by non-cardiac diseases;\n* 2.Patients with any contraindication to Fecal Microbiota Transplantation (FMT):\n\n  1. Patients with severe intestinal barrier damage induced by various causes, such as sepsis, active massive gastrointestinal bleeding, intestinal perforation;\n  2. Patients diagnosed with fulminant colitis or toxic megacolon;\n  3. Patients unable to tolerate enteral nutrition meeting 50% of calorie requirements due to severe diarrhea, significant fibrous intestinal stenosis, severe gastrointestinal hemorrhage, high-output intestinal fistula and other conditions;\n  4. Patients with congenital or acquired immunodeficiency diseases;\n  5. Patients receiving high-risk immunosuppressive or cytotoxic drugs recently, such as rituximab, doxorubicin, or moderate-to-high dose steroids (prednisone ≥ 20 mg\u002Fd) administered continuously for more than 4 weeks;\n  6. Severely immunosuppressed patients with neutrophil count \\\u003C 1500\u002Fmm³;\n* 3.History of myocardial infarction, coronary artery bypass grafting, or any event that may reduce LVEF within 6 months before enrollment (unless LVEF ≥ 50% was confirmed);\n* 4.Received valve replacement surgery within 6 months before enrollment;\n* 5.Poorly controlled blood pressure (SBP ≥ 180 mmHg or DBP ≥ 100 mmHg);\n* 6.Current acute decompensated heart failure requiring intervention;\n* 7.Resting heart rate \\> 120 beats per minute, or complicated with malignant arrhythmia;\n* 8.Significant coronary artery disease requiring PCI revascularization;\n* 9.Severe renal insufficiency (serum creatinine \\> 442 μmol\u002FL) or patients on dialysis;\n* 10.Pre-existing gastrointestinal diseases, including ulcerative colitis, Crohn's disease, irritable bowel syndrome, chronic diarrhea;\n* 11.Current malignant tumors requiring anti-tumor treatment;\n* 12.Complicated with acute diseases or acute exacerbation of chronic diseases at present;\n* 13.Participation in other interventional clinical trials or oral intake of probiotic preparations within the past 3 months.","60 Years",{"count":177,"type":21},50,[179,86],"PHASE1","This is a single-center, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of fecal microbiota transplantation (FMT) in elderly patients with heart failure with preserved ejection fraction (HFpEF).\n\nHFpEF is a common type of heart failure in older adults, often associated with poor quality of life and frequent hospitalizations. Recent research suggests that changes in gut bacteria may contribute to the progression of HFpEF. FMT aims to restore a healthy gut microbiome, which may improve heart function and reduce symptoms.\n\nParticipants will be randomly assigned to receive either FMT or a placebo treatment. The primary goal is to compare changes in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score between the two groups at 20 weeks. Secondary goals include assessing improvements in exercise capacity (6-minute walk test), NYHA functional class, and safety outcomes.\n\nThe study will enroll 50 elderly patients (aged ≥60 years) with confirmed HFpEF. All participants will receive standard medical care for HFpEF throughout the study. This trial is sponsored by The First Affiliated Hospital of Air Force Medical University and conducted in accordance with ethical standards.",[182,28],"Heart Failure With Preserved Ejection Fraction (HFPEF)",[184,63,185,186],"Heart Failure with Preserved Ejection Fraction","Fecal Microbiota Transplantation","FMT","2026-06-01",{"date":189,"type":38},"2026-06-05",{"date":191,"type":21},"2026-06",{"date":144,"type":21},{"name":194,"class":76},"The First Affiliated Hospital of Air Force Medicial University",{"id":196,"slug":4,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":204,"briefSummary":205,"conditions":206,"keywords":207,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":77},"100630621","NCT07490054","Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure","An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of Intestinal Microbiota Transplantation In Patients With Chronic Heart Failure","IMT","Inclusion Criteria:\n\n* Diagnosis of Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Reduced Ejection Fraction (HFpEF), New York Heart Association Class II-IV\n* On stable treatment for CHF for one month prior to enrollment\n* Able to swallow capsules\n* Able to provide blood sample and fecal sample\n* Stated willingness to comply with all study procedures and availability for the duration of trial to follow-up by telephone, in-person, email, and\u002For video visits or correspondence.\n\nExclusion Criteria:\n\n* Dysphagia to pills\n* Clinically active inflammatory bowel disease\n* History of celiac disease\n* Listed for transplant, and anticipated transplant listing or LVAD placement in the next 6 months\n* Acute myocarditis\n* Infiltrative and hypertrophic cardiomyopathies\n* Renal disease requiring dialysis\n* Pregnancy or breastfeeding. A pregnancy test will be obtained from females of child-bearing potential at the screening visit or day 1 (prior to the receipt of IMT). Patients with a positive pregnancy test will be excluded. A negative result will be required for subjects who are females of child-bearing potential to receive IMT treatment. Patients will be counseled to avoid pregnancy which is the standard of care for patients with CHF.\n* Life expectancy of \\\u003C 6 months\n* Presence of ileostomy or colostomy\n* Patients on immunosuppressants (calcineurin inhibitors, prednisone ≥ 20 mg\u002Fday, methotrexate, azathioprine, immunosuppressive biologics, JAK inhibitors).\n* Patients with neutropenia (an absolute neutrophil count \\\u003C 0.5 x 109 cells\u002FL) obtained on a complete blood count with differential at screening\n* History of solid organ or bone marrow transplant\n* Anticipated recurrent antibiotic use (patients with frequent urinary tract infections or sinusitis)\n* History of severe anaphylactic food allergy\n* Patients receiving cancer chemotherapy, immunotherapy, or radiation",{"count":203,"type":21},40,[179],"The purpose of this study is to determine whether people with CHF, who often have different gut bacteria from healthy, would benefit from replacing their gut bacteria with healthy donor bacteria (also known as Intestinal Microbiota Transplantation - IMT). IMT aims to restore healthy gut bacteria in patients with CHF, with previous studies showing its effectiveness, but further research is needed. IMT is an approved treatment for patients with infectious diarrhea. More than 10,000 IMTs are performed every year in the US. However IMT is not approved for patients with CHF, and thus considered investigational.",[28],[27,208,209,184],"Intestinal Microbiota Transplantation","Heart Failure with Reduced Ejection Fraction","2026-04-29",{"date":212,"type":38},"2026-05-05",{"date":214,"type":38},"2025-09-01",{"date":216,"type":21},"2027-11",{"name":218,"class":76},"Melana Yuzefpolskaya, MD",{"id":220,"slug":4,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":175,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":245},"100576428","NCT06785168","Effects of Resistance Training on Sarcopenia in Older Patients With Chronic Heart Failure","Effects of Resistance Training on Sarcopenia in Older Patients With Chronic Heart Failure: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged ≥ 60 years old\n* Meet the diagnostic criteria of 2019 AWGS2 sarcopenia, can be diagnosed once meeting (1) + (2) or (1) + (3) or (1) + (2) + (3): (1) Appendicular skeletal muscle mass (ASM): dual-energy X-ray absorptiometry (DXA) (male \\\u003C7.0 kg\u002Fm², female \\\u003C5.7 kg\u002Fm²). (2) Muscle strength: handgrip strength (male \\\u003C28.0 kg, female \\\u003C18.0 kg). (3) Physical performance: 6-meter walking speed \\\u003C1.0 m\u002Fs.\n* Meet the diagnostic criteria of heart failure following ESC 2021.\n* Clearly understand the content and purpose of the study and sign the informed consent form.\n\nExclusion Criteria: There are contraindications for Exercise Testing in patients with stable heart failure according to ACSM 2022:\n\n* Early stage after acute coronary syndrome (within the first 2 days)\n* Unstable coronary artery disease\n* Decompensated heart failure\n* Acute venous thrombosis or recent arterial embolism (pulmonary or systemic)\n* Acute myocarditis, pericarditis, endocarditis\n* Aortic dissection of the valve\n* Severe symptomatic aortic stenosis\n* Acute systemic disease or fever\n* Uncontrolled or life-threatening atrial or ventricular arrhythmias (including new-onset atrial fibrillation or flutter)\n* Uncontrolled tachycardia (resting heart rate \\> 120 beats per minute)\n* Third-degree AV block\n* Uncontrolled diabetes\n* Symptomatic orthostatic hypotension (\\> 20 mmHg)\n* Gradually increasing fatigue during exercise or dyspnea at rest or with exertion within the past 3-5 days\n* Significant myocardial ischemia at low workloads \\\u003C 2 METs or 50W\n* Relative contraindications according to ACSM 2022:\n* Weight gain ≥ 1.8 kg in the past 1-3 days\n* Simultaneous use of continuous or intermittent Dobutamine\n* Decrease in blood pressure with exercise\n* NYHA IV heart failure\n* Complex ventricular arrhythmias at rest or with exertion\n* Resting heart rate ≥ 100 bpm when lying down\n* Comorbidities that limit exercise\n* Severe obstructive hypertrophic cardiomyopathy\n* Have participated in a cardiovascular rehabilitation program within the last 6 months\n* Do not agree to participate in the study",{"count":226,"type":21},146,[24],"The goal of study is to evaluate the effects of an eight-week machine-based resistance training program on managing sarcopenia in older outpatients with chronic heart failure (HF) at Military Hospital 175.",[230,28],"Sarcopenia in Elderly",[232,31,233,234,235],"sarcopenia","machine-based resistance training","age over 60","outpatient","2026-04-25",{"date":238,"type":38},"2026-04-30",{"date":240,"type":38},"2024-12-24",{"date":242,"type":21},"2027-12-31",{"name":244,"class":76},"Kieu Nguyen Dang Phuong",2,{"id":247,"slug":4,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":252,"targetDuration":254,"studyType":136,"phases":4,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":263,"locationsCount":77},"100568574","NCT06683001","National Heart Failure Registry","CHaracterization Of the STate of the System of Care for Patients With Chronic Heart Failure in the Regions of the Russian Federation: Identification, Diagnostics, Treatment, Observation","Inclusion Criteria:\n\n* Any stage and\u002For any class of CHF\n\nExclusion Criteria:\n\n* Subjects whose source records cant be obtained for the analysis",{"count":253,"type":21},20000,"3 Years","A prospective-retrospective observational registry of patients diagnosed with chronic heart failure in the regions of the Russian Federation.\n\nThe study is non-interventional and does not involve any interventions in clinical practice, the choice of treatment methods (including the type of medical device used and the method of surgical intervention) and examination.\n\nA control observation group is not intended.",[28],"2026-04-08",{"date":259,"type":38},"2026-04-13",{"date":261,"type":38},"2024-10-01",{"date":242,"type":21},{"name":264,"class":265},"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","OTHER_GOV",{"id":267,"slug":4,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":275,"conditions":276,"keywords":277,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":77},"100398668","NCT04471129","Non-invasive Ventilation and High-speed Oxygen Therapy Effects on Heart Function - HiFlow-Heart Study","HiFlow-Heart","Inclusion Criteria:\n\n1. Major patient\n2. Patient who has undergone cardiac surgery with extracorporeal circulation for more than 24 hours and has been extubated for at least 6 hours.\n3. Pre-operative heart failure with left ventricular ejection fraction \\\u003C 40%.\n4. Invasive monitoring by pulmonary arterial catheter (Swan-Ganz) with transpulmonary thermodilution and by radial arterial catheter intended for use in the intra- and post-operative monitoring of the patient.\n5. Treatment with conventional oxygen therapy (O2C) without an increase in O2 flow for more than 30 minuts, without signs of hypoxemia (SpO292%)\n6. Stable hemodynamic parameters: no changes in hemodynamic parameters (arterial pressures and pulmonary and cardiac index) by more than 10% over the 30 minutes prior to inclusion and no increase in cardiotropic medication for at least 30 minutes.\n7. Patient with an oxygenation rate ≤ 6L\n8. For women of child-bearing age: negative pregnancy test at inclusion\n9. Person who has read and understood the information letter and signed the consent form\n10. Affiliation to a social security scheme\n\nExclusion Criteria:\n\n1. Contraindication to the use of NIV or HFO\n2. Patient with orotracheal intubation or tracheotomy\n3. Renal failure with hemodialysis or hemofiltration\n4. Uncontrolled state of shock (PAS\\\u003C90 mmHg and\u002For cardiac index\\\u003C1.8 L\u002Fmin\u002Fm² and\u002For norepinephrine\\>0.2 μg\u002Fkg\u002Fmin and\u002For dobutamine\\>10 μg\u002Fkg\u002Fmin)\n5. Acute respiratory failure as defined by :\n\n   * clinical signs: respiratory rate \\>35\u002Fmin, signs of struggle, SpO2\\\u003C92% on O2C\n   * indication for treatment with NIV or HFO at the discretion of the clinician\n   * oxygen dependency requiring O2C\\>6L\u002Fmin O2C flow at the oxygen mask\n6. Chronic advanced respiratory disease\n7. Chronic treatment with NIV or CPAP at home\n8. Non-operated aortic or mitral insufficiency ≥ II\u002FIV\n9. Administration of loop diuretics within 3 hours prior to inclusion for intravenous forms and within 6 hours for oral forms.\n10. Presence of altered consciousness defined by a Glasgow score \\\u003C 15\u002F15 or cognitive dysfunction defined by a CAM-ICU score \\> 0\u002F4\n11. Pregnant or parturient or nursing woman or proven lack of effective contraception\n12. Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection \u002F subtutorship or guardianship\n13. Person participating in another trial \u002F having participated in another trial that may interfere with the procedures that are the subject of the research within a 4-week time frame",{"count":273,"type":21},30,[24],"The investigators hypothesize that the airway pressures generated by High Flow Oxygen Therapy could have a beneficial impact in patients with heart failure, particularly by lowering capillary pulmonary arterial pressures. However, results compared to Non-Invasive Ventilation are difficult to predict due to the lack of data in the literature.",[28],[31,278,279,280],"heart surgery","invasive mechanical ventilation","high flow oxygen therapy","2026-03-13",{"date":283,"type":38},"2026-03-16",{"date":285,"type":38},"2020-09-16",{"date":287,"type":21},"2026-09-16",{"name":289,"class":76},"University Hospital, Rouen",{"id":291,"slug":4,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":296,"sex":17,"minAge":297,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":77},"100629552","NCT07476157","A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-118 Compared to AD-1181 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* Subjects aged 19 years or older and under 65 years at the screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"19 Years","64 Years",{"count":300,"type":21},70,[179],"A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 Under Fasted Conditions in Healthy Adult Subjects",[28],"2026-03-12",{"date":306,"type":38},"2026-03-17",{"date":308,"type":21},"2026-04",{"date":310,"type":21},"2026-05",{"name":312,"class":45},"Addpharma Inc.",{"id":314,"slug":4,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":17,"minAge":297,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":322,"conditions":323,"keywords":327,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":77},"100586000","NCT06909682","AI-Based Monitoring System for Chronic Heart Failure With Advanced Wearable and Mini-Invasive Devices","Smart Monitoring and Analysis System Based on Artificial Intelligence for Patients With Chronic Heart Failure Using Advanced Mini-Invasive and Wearable Medical Devices","SMART-CARE","Inclusion Criteria\n\n* Age ≥ 18 years (adults of any sex)\n* Confirmed diagnosis of chronic heart failure (CHF) for at least 6 months prior to screening\n* Stable on optimized heart failure therapy for at least one month before enrollment\n* Any left ventricular ejection fraction (LVEF) classification, including:\n\n  * Heart Failure with Reduced Ejection Fraction (HFrEF)\n  * Heart Failure with Mid-Range Ejection Fraction (HFmrEF)\n  * Heart Failure with Preserved Ejection Fraction (HFpEF)\n* NYHA Functional Class I, II, or III\n* History of at least one hospital admission or outpatient visit in the past 12 months requiring intravenous (IV) diuretics, vasodilators, or inotropes for CHF exacerbation\n* Ability to provide written informed consent or availability of a legally authorized representative Exclusion Criteria\n* NYHA Functional Class IV or anticipated heart transplant or ventricular assist device (VAD) implantation within 6 months of screening\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or dialysis dependence\n* Terminal comorbidities (e.g., advanced cancer, end-stage pulmonary disease) significantly limiting life expectancy\n* Pregnancy\n* Presence of skin conditions or allergies preventing prolonged use of a wearable device\n* Inability to comply with study procedures (e.g., cognitive impairment, significant psychiatric disorders)",{"count":321,"type":21},205,"The goal of this observational, multicenter study is to evaluate whether AI-driven remote monitoring using a mini-invasive wearable device can improve clinical outcomes in adult patients (≥18 years) with chronic heart failure (CHF).\n\nThe main questions it aims to answer are:\n\n* Can continuous remote monitoring reduce hospital admissions (emergency visits and hospitalizations) by 20% compared to standard care?\n* Does wearable-based remote monitoring improve functional, biochemical, and instrumental parameters in CHF patients? Researchers will compare patients using the wearable device (intervention group) to those receiving standard clinical follow-up (control group) to assess whether AI-driven monitoring leads to fewer hospitalizations, better disease management, and improved quality of life.\n\nParticipants will:\n\n* Wear the EmbracePlus (Empatica Inc.) device continuously for six months (intervention group only).\n* Have their biometric data (SpO₂, HRV, EDA, respiratory rate, temperature, sleep quality) monitored remotely.\n* Receive automated alerts and teleconsultations if abnormal physiological changes are detected.\n* Attend scheduled follow-up visits (remote and in-person) for clinical evaluation and treatment adjustments.\n\nThe study aims to provide real-world evidence on whether integrating wearable health technology with AI analytics can enhance CHF management and improve patient outcomes.",[28,324,325,182,326],"Cardiovascular Diseases","Heart Failure With Reduced Ejection Fraction (HFrEF)","Congestive Heart Failure Chronic",[328,329,330,331,332,333,334,335,336,337,338,339,340],"Wearable Medical Devices","Remote Patient Monitoring","Artificial Intelligence in Cardiology","Smart Wearables for Healthcare","Observational Study in Heart Failure","AI-Based Predictive Modeling","Telemedicine in Heart Failure","Non-Invasive Health Monitoring","Personalized Medicine for CHF","Quality of Life Improvement in Heart Failure","Heart Failure Readmission Prevention","Telehealth in Chronic Disease Management","Digital Health Solutions for Heart Disease","2026-03-09",{"date":343,"type":38},"2026-03-11",{"date":345,"type":38},"2025-08-01",{"date":347,"type":21},"2027-02-02",{"name":349,"class":76},"University of Salerno",{"id":351,"slug":4,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":296,"sex":17,"minAge":355,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":77},"100434792","NCT04941794","Biomarkers as Predictors of Chronic Heart Failure in Patients With Type 2 Diabetes","Inclusion Criteria:\n\n* Type 2 diabetes\n* age \\> 50 years\n\nExclusion Criteria:\n\n* History of acute or chronic heart failure\n* History of ischemic heart disease","50 Years",{"count":357,"type":21},500,"A cohort study on patients with type 2 diabetes to investigate possible biomarkers as predictors of chronic heart failure.",[360,28],"Type 2 Diabetes","2026-03-06",{"date":363,"type":38},"2026-03-10",{"date":365,"type":38},"2021-07-01",{"date":367,"type":21},"2027-07",{"name":369,"class":265},"Regionshospital Nordjylland",{"id":371,"slug":4,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":22,"phases":379,"briefSummary":380,"conditions":381,"keywords":382,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":77},"100626327","NCT07434193","Biventricular or Left Bundle Branch Pacing to Assess the Effect of Cardiac Resynchronization Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation","Biventricular or Left Bundle Branch Pacing to Assess the Effect of Cardiac Resynchronization Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation- the BUDAPEST CRT TAVI Trial","BUDAPEST-TAVI","Inclusion Criteria:\n\n* Age over 18 years\n* Successful and complication-free TAVI implantation for significant aortic stenosis\n* Signed informed consent after detailed patient information\n* New-onset LBBB wider than 130 ms after TAVI, persisting at the time of planned discharge (assessed postoperatively on or after day 5)(21)\n* Mildly reduced left ventricular systolic function on echocardiography at the planned time of discharge (at the earliest on postoperative day 5), with EF between 35% and 55%\n\nExclusion Criteria:\n\n* Pre-existing right bundle branch block, or prior pacemaker\u002FICD implantation associated with significant (\\>20%) ventricular pacing\n\n  * Progression of LBBB during hospitalization to a degree indicating pacemaker implantation (e.g., Mobitz II or third-degree AV block, alternating bundle branch block) before the planned discharge date\n  * Concomitant severe valvular disease of other valves (mitral, pulmonary, or tricuspid)\n  * Severe infection and\u002For septic state\n  * TAVI-associated stroke\n  * More than moderate paravalvular leak of the TAVI valve on postoperative echocardiography\n  * EF \\\u003C 35% or \\> 55% on echocardiography performed at the planned time of discharge\n  * GOLD stage IV COPD\n  * Chronic renal failure requiring regular dialysis\n  * Concurrent participation in another clinical trial",{"count":378,"type":21},360,[24],"In this prospective, randomized, multicenter, open-label interventional clinical trial, the investigators' aim to test the effect of Cardiac Resynchronization Therapy (CRT) in cases of new-onset and persistent Left Bundle Branch Block (LBBB) occurring in the context of Transcatheter Aortic Valve Implantation (TAVI), in patients with moderately reduced left ventricular systolic function (35% \\\u003C EF \\\u003C 55%). The investigators hypothesize that in patients with persistent LBBB developing after TAVI and mildly reduced left ventricular systolic function (35% \\\u003C EF \\\u003C 55%), early postoperative CRT implantation favorably influences the process of myocardial reverse remodeling by reducing electromechanical dyssynchrony, thereby decreasing the combined endpoint of heart failure-related hospitalizations and mortality at one year.",[28],[383],"Cardiac Resynchronization Therapy","2026-02-22",{"date":386,"type":38},"2026-02-25",{"date":388,"type":38},"2025-11-19",{"date":390,"type":21},"2033-01-31",{"name":392,"class":76},"Semmelweis University Heart and Vascular Center",{"id":394,"slug":4,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":22,"phases":402,"briefSummary":403,"conditions":404,"keywords":405,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":424,"locationsCount":77},"100624154","NCT07405944","Vericiguat and Reverse Remodeling Indices in Heart Failure","Vericiguat's Effects on Reverse Remodeling Indices: Pathophysiologic Approach to Treatment of Heart Failure With Reduced Ejection Fraction","VERI-PATH","Inclusion Criteria:\n\n* Written informed consent from an adult patient (≥ 18 years old) to participate in the clinical study,\n* Stable HFrEF defined as no heart failure worsening in the 6 months before randomization that required hospitalization or outpatient diuretic treatment,\n* Confirmed diagnosis of chronic heart failure with reduced ejection fraction (LVEF ≤ 40%, confirmed by echocardiography) within 12 months before randomization,\n* Stable GDMT for HFrEF for at least 3 months prior to randomisation.\n\nExclusion Criteria:\n\n* Systolic blood pressure \\\u003C 100 mmHg or symptomatic hypotension,\n* Current or planned use of long-acting nitrates, soluble guanylate cyclase stimulators, or phosphodiesterase type V inhibitors,\n* Known allergy\u002Fhypersensitivity to soluble guanylate cyclase stimulators,\n* Awaiting heart transplantation or dependence on continuous inotropic therapy\n* Cardiac amyloidosis, sarcoidosis, myocarditis, stress cardiomyopathy, or tachycardic cardiomyopathy,\n* Acute coronary syndrome, coronary artery bypass grafting, or percutaneous coronary intervention in the past three months before randomisation,\n* Long-term mechanical circulatory support of the left ventricle,\n* Active infection,\n* Chronic kidney disease stage 4 or 5, and\n* Advanced liver failure classified as Child-Pugh B or C.",{"count":401,"type":21},60,[58],"The goal of this clinical trial is to investigate how vericiguat benefits adults with stable heart failure with reduced ejection fraction (HFrEF) who are already receiving guideline-directed medical therapy.\n\nThe main questions are:\n\n* Does vericiguat improve right ventricular systolic function, measured by tricuspid annular plane systolic excursion (TAPSE)?\n* Does vericiguat favourably influence myocardial remodeling, fibrosis, angiogenesis, inflammation, metabolism, renal function, and hematologic balance?\n* Do genetic and oxidative stress profiles modify treatment response? Researchers will compare a group receiving vericiguat plus usual care with a group receiving usual care alone to assess structural, functional, and biomarker changes over 12 months.\n\nParticipants will:\n\n* Have blood drawn at baseline and follow-up visits for biomarker, metabolomic, genetic, transcriptomic, and hematologic analyses, including platelet function testing\n* Perform oral glucose tolerance tests (OGTT) to assess insulin resistance\n* Undergo echocardiography, cardiac magnetic resonance imaging, and cardiac scintigraphy to evaluate heart structure, function, and perfusion\n* Attend follow-up visits at 1, 3, 6, and 12 months Open-label extension: After the 12-month randomized phase, participants originally assigned to usual care will be offered open-label vericiguat and followed for an additional 12 months. This exploratory extension will reassess study outcomes to evaluate the consistency and magnitude of response to vericiguat in the prior control cohort.",[325,28],[406,407,408,409,410,411,412,413,414,415,416,417],"Vericiguat","Soluble Guanylate Cyclase","Cyclic GMP","Reverse Remodeling","Cardiac Magnetic Resonance Imaging","Myocardial Perfusion Imaging","Fibrosis","Inflammation","Angiogenesis","Oxidative Stress","Immunomodulation","Insulin Resistance","2026-02-08",{"date":420,"type":38},"2026-02-12",{"date":422,"type":38},"2025-11-01",{"date":242,"type":21},{"name":425,"class":76},"University Medical Centre Ljubljana",{"id":427,"slug":4,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":17,"minAge":297,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":434,"conditions":435,"keywords":436,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":77},"100622147","NCT07379840","A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea","Post Marketing Surveillance for Finerenone Chronic Heart Failure in Korea","Inclusion criteria:\n\n* Adults aged 19 years or older\n* With informed consent from subject or legal representative (Prioritizing patient consent)\n* Finerenone naïve patients who are prescribed finerenone for treatment of chronic HF with LVEF ≥40%\n\nExclusion criteria:\n\n* Contraindication according to the local label (including known hypersensitivity to the drug substance or any of its components)\n* Patients participating in an investigational program with interventions outside of routine clinical practice (NYHA classes II-IV) in accordance with local label",{"count":433,"type":21},300,"This is an observational study in which data from people with chronic heart failure (HF) with left ventricular ejection fraction (LVEF) ≥ 40%. who will be receiving finerenone are studied.\n\nThe study is conducted to check the safety of finerenone after it is approved and available in South Korea.\n\nObservational studies use data that are collected as part of routine medical care and participants do not receive any advice or any changes to healthcare as part of the study.\n\nIn this study, the data will be collected from participants who are receiving their usual treatment with finerenone as prescribed by their doctor according to the approved product information.\n\nHeart failure with LVEF ≥ 40% is a condition which occurs when the left side of the heart does not pump blood out to the body as well as it should. Over time, the body does not get the amount of oxygen it needs. This can lead to shortness of breath and tiredness, making it difficult for people to do their daily tasks.\n\nThe study drug, finerenone, is already approved for doctors to prescribe to people with chronic heart failure. It works by blocking a specific receptor in the body called the mineralocorticoid receptor (MR). This helps reduce harmful effects in the heart, kidneys and blood vessels. Finerenone is different from older medicines in this group because it is more selective and may have fewer side effects, such as problems with the kidneys or high potassium levels in the blood.\n\nThe participants in this study will receive finerenone as prescribed independently by their doctors during routine practice according to the approved product information.\n\nThere have been studies in which researchers studied the effect and safety of finerenone in participants with chronic heart failure with LVEF ≥ 40%. These studies, however, included only a small number of South Korean participants. In this study, researchers will specifically gather data from South Korean participants to further understand the safety of finerenone.\n\nThe main purpose of this study is to learn more about how safe and effective finerenone is in adults with chronic heart failure with LVEF ≥ 40% in South Korea within approved local label when used in everyday medical practice.\n\nTo do this, researchers will collect any side effects or health problems that happen while patients are taking finerenone, and whether they are related to finerenone.\n\nIn addition, doctors will also look at how well finerenone works by measuring:\n\n* Changes in investigator's treatment satisfaction with the treatment over time, including improvements in symptoms, quality of life and overall health status.\n* Time to dose change of finerenone (for example, increasing the dose if needed).\n\nData will be collected from participants over one year after they enroll in the study or until they choose to leave the study. The data will come from participant's medical records or by interviewing the patient.\n\nIn this study, only available data from routine care will be collected. No visits or tests are required as part of this study.",[28],[27,437],"Post-Marketing Surveillance","2026-01-30",{"date":440,"type":38},"2026-02-03",{"date":442,"type":38},"2025-12-23",{"date":444,"type":21},"2027-09-30",{"name":146,"class":45},{"id":447,"slug":4,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":22,"phases":455,"briefSummary":456,"conditions":457,"keywords":458,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":77},"100517563","NCT06019169","Impact of YOGA on the Quality of Life and Well-being of Heart Failure Patients","Randomized Pilot Trial: Impact of YOGA on the Quality of Life and Well-being of Heart Failure Patients","YOG-IC","Inclusion Criteria:\n\n* Patient ≥18 years old\n* Chronic heart failure patient defined by: Most recent LVEF ≤50% (regardless of measurement method)\n* Stabilized (last episode of acute heart failure dating back more than a month) in NYHA stage I to III dyspnoea, ambulatory, discharged from hospital for \\> 1 month\n* Drug treatment optimized according to the judgment of the investigator\n* Ability to participate in activities as proposed (remote or face-to-face)\n* Patient affiliated with a social security scheme\n* Written consent to participate\n\nExclusion Criteria:\n\n* Patients who have practiced yoga regularly (\\> once a month) in the six months prior to selection.\n* Current pregnancy \u002F lactation\n* Etiology of heart failure: hypertrophic cardiomyopathy, restrictive heart disease or severe curable valve disease\n* Severe renal impairment GFR\\\u003C25ml\u002Fmin\u002F1.73 m2 or on dialysis.\n* Persons subject to legal protection measures (guardianship, curatorship)\n* Person not \"receptive\" to the practice of yoga\n* Participation in intervention research",{"count":454,"type":21},66,[24],"Heart failure (HF) is a chronic disease that has a strong impact on quality of life and is often accompanied by anxiety and depression symptoms that can contribute to poor treatment compliance. The overall management of heart failure is currently part of the recommendations and, alongside drug therapy and electrical devices that can be proposed, lifestyle changes (diet, physical activity) can help improve well-being. and perhaps patient prognosis. Yoga is an ancient practice, known to improve the emotional and physical well-being of individuals. There is no formal medical contraindication to this practice, which can be perfectly adapted to the patient's condition. However, very few patients with heart failure practice yoga. A few randomized trials with small numbers as well as the combined analysis of several studies have shown the benefit of yoga in heart failure. The main objective of the research is to demonstrate the improvement in the quality of life induced by the regular practice of yoga in the management of stabilized chronic heart failure patients. Secondly, we will evaluate the effectiveness of regular yoga practice on improving the clinical condition of chronic heart failure patients.",[28],[28,459,460,461],"Yoga","randomized","SF36","2026-01-13",{"date":464,"type":38},"2026-01-15",{"date":466,"type":38},"2024-03-26",{"date":468,"type":21},"2027-04-26",{"name":470,"class":76},"Assistance Publique - Hôpitaux de Paris",{"id":472,"slug":4,"hasResults":11,"nctId":473,"briefTitle":474,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":296,"sex":17,"minAge":54,"maxAge":477,"enrollmentInfo":478,"targetDuration":479,"studyType":136,"phases":4,"briefSummary":480,"conditions":481,"keywords":483,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":77},"100620243","NCT07355088","Precision Subtyping and Prognostic Study of Heart Failure Based on Multi-Omics Integration and Clinical Indicators: A Prospective Single-Center Cohort Study","HF-MultiOmics","Inclusion Criteria:(1)For chronic heart failure (CHF) patients:1.Meet the 2022 European Society of Cardiology (ESC) diagnostic criteria for CHF, classified into heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF), and heart failure with preserved ejection fraction (HFpEF) per ESC guidelines;2.Aged 18 to 80 years (inclusive);3.Able to provide written informed consent independently (or via a legal guardian if cognitively impaired, with a Mini-Mental State Examination \\[MMSE\\] score ≥ 24).\n\n(2)For healthy controls:1.No history of cardiovascular disease, confirmed by medical history review and baseline echocardiography;2.Aged 18 to 80 years (inclusive), matched 1:2 with CHF patients by age and gender;3.Able to provide written informed consent.\n\nExclusion Criteria:(1)Acute decompensated heart failure (admitted for acute HF exacerbation within 72 hours prior to enrollment);(2)End-stage renal disease, defined as an estimated glomerular filtration rate (eGFR) \\\u003C 15 mL\u002Fmin\u002F1.73m² (confirmed by serum creatinine testing);(3)Active malignancies (receiving systemic treatment within 6 months prior to enrollment) or severe systemic diseases (e.g., severe liver failure, active autoimmune diseases);(4)Antibiotic use within 2 weeks prior to enrollment (may interfere with gut microbiome analysis);(5)Inability to complete 12-month follow-up (e.g., planned long-term overseas residence) or provide required biological samples (e.g., venous blood, fecal samples).","80 Years",{"count":155,"type":21},"12 Months","This is a prospective single-center cohort study conducted at The First Affiliated Hospital of Xinjiang Medical University, aiming to enroll 400 patients with chronic heart failure (including HFrEF, HFmrEF, HFpEF) and 200 healthy controls.We will collect clinical data (e.g., NYHA class, NT-proBNP), multi-omics samples (genome, proteome, metabolome, gut microbiome), and imaging indicators (e.g., EAT density, myocardial strain) from participants at baseline. For patients treated with SGLT2 inhibitors, we will also track dynamic changes in multi-omics during follow-up.The main purpose is to build a composite risk prediction model (integrating multi-omics and clinical indicators) to predict the 1-year composite endpoint (heart failure rehospitalization or all-cause death). Secondary goals include identifying specific molecular profiles related to heart failure phenotypes, exploring the \"gut-heart axis\" mechanism, and finding early biomarkers for SGLT2 inhibitor response.All participants will be followed up for at least 12 months, and the study will strictly comply with ethical norms and protect the privacy of participants.",[28,325,182,482],"Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)",[28,484,485,486,487,488,489],"Multi-omics","Gut-heart axis","SGLT2 inhibitors","Risk prediction model","Epicardial Adipose Tissue","Myocardial Strain","2026-01-12",{"date":492,"type":38},"2026-01-21",{"date":494,"type":21},"2026-01-01",{"date":496,"type":21},"2028-03-01",{"name":498,"class":76},"Xinjiang Medical University",{"id":500,"slug":4,"hasResults":11,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":477,"enrollmentInfo":505,"targetDuration":4,"studyType":22,"phases":507,"briefSummary":508,"conditions":509,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":521},"100613343","NCT07265349","A Phase I\u002FII Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure","A Phase I\u002FII Clinical Trial to Evaluate the Safety and Efficacy of Intramyocardial Injection of Human Umbilical Cord Mesenchymal Stem Cells (HucMSCs) Combined With Coronary Artery Bypass Grafting in the Treatment of Chronic Heart Failure Caused by Chronic Ischemic Cardiomyopathy","Inclusion Criteria:\n\n* 1\\) Age from 18 to 80 years, both genders are eligible ;\n* 2\\) Clinically judged to be suitable for CABG treatment due to chronic ischemic cardiomyopathy;\n* 3\\) LVEF (left ventricular ejection fraction) is ≤ 40% as indicated by echocardiography (modified Simpson method) or cardiac magnetic resonance (CMR);\n* 4\\) NYHA (New York Heart Association) cardiac function classification of grade II-IV;\n* 5\\) Patients or their legal guardians agreed to participate in this trial and signed the informed consent form.\n\nMajor exclusion Criteria:\n\n* 1\\) Severe left ventricular dysfunction, with LVEF ≤ 20% (based on the UCG or CMR examination results during the screening period);\n* 2\\) Non-ischemic chronic left heart dysfunction, including but not limited to acute left heart dysfunction, dilated cardiomyopathy, severe right heart dysfunction (such as bilateral lower extremity edema accompanied by jugular vein distension, liver enlargement, etc.) or severe pulmonary hypertension (PASP \\> 70 mmHg);\n* 3\\) Clinically determined that other surgical procedures need to be performed simultaneously during CABG surgery, including but not limited to congenital heart disease requiring concurrent surgical intervention, heart valve disease, ventricular aneurysm, ventricular septal perforation, papillary muscle dysfunction, aortic dissection, intracardiac mass, thrombus or neoplasm；\n* 4\\) Acute ST-segment elevation myocardial infarction or stroke event within 1 month before enrollment；\n* 5\\) Uncontrolled malignant arrhythmia;\n* 6)have undergone or are awaiting heart transplantation or implantation of a left ventricular assist device (LVAD).",{"count":506,"type":21},51,[179,86],"B2278 is a human umbilical cord mesenchymal stem cell (HucMSCs) injection derived from the umbilical cord. It has the advantages of stronger immune regulation, stronger expansion capacity, lower immunogenicity, and greater accessibility. The preliminary research results indicated that the B2278 injection promote the polarization of macrophages towards a reparative state through paracrine action, directly promote angiogenesis and inhibited inflammatory responses, thereby exerting effects on myocardial repair and treatment of heart failure, and it is also safe and well-tolerated.\n\nThis trial is a multi-center I\u002FII phase clinical trial of the human umbilical cord mesenchymal stem cell injection solution, aiming to explore the dosage and regimen for the intramyocardial injection of B2278 in combination with coronary artery bypass grafting surgery for the treatment of chronic heart failure caused by chronic ischemic cardiomyopathy, and to evaluate the safety, tolerance and efficacy of allogeneic intramyocardial injection of the human umbilical cord mesenchymal stem cell injection solution in patients with chronic ischemic heart failure.",[510,28,511],"Coronary Artery Bypass Grafting (CABG)","Chronic Ischemic Cardiomyopathy","2026-01-07",{"date":514,"type":38},"2026-01-09",{"date":516,"type":38},"2025-12-26",{"date":518,"type":21},"2027-08-01",{"name":520,"class":45},"Tasly Pharmaceutical Group Co., Ltd",4,{"id":523,"slug":4,"hasResults":11,"nctId":524,"briefTitle":525,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":22,"phases":529,"briefSummary":530,"conditions":531,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":77},"100618001","NCT07325942","Effectiveness of Low -Versus High -Volume High -Intensity Interval Training in Patients With Chronic Heart Failure","Inclusion Criteria:\n\n1. Chronic stable heart failure patient with reduced ejection fraction (EF \\\u003C40)\n2. Age Above 18 years old\n3. Both males and females\n4. The ability to provide informed consent\n\nExclusion Criteria:\n\n1. Based on the Scientific Statement from the American Heart Association: contraindications for exercise Testing and Training. (Fletcher et al., 2013)\n\n   1. Acute myocardial infarction (MI), within 2 days\n   2. Ongoing unstable angina\n   3. Uncontrolled cardiac tachy or brady arrhythmia with hemodynamic compromise\n   4. Active endocarditis\n   5. Symptomatic severe aortic stenosis\n   6. Decompensated heart failure\n   7. Acute pulmonary embolism, pulmonary infarction, or deep vein thrombosis\n   8. Acute myocarditis or pericarditis\n   9. Acute aortic dissection\n   10. Physical disability that precludes safe and adequate testing or training\n   11. Known obstructive left main coronary artery stenosis\n   12. Hypertrophic obstructive cardiomyopathy with severe resting gradient\n   13. Recent stroke or transient ischemic attack\n   14. Mental impairment with limited ability to cooperate\n   15. Resting hypertension with systolic or diastolic blood pressures \\>200\u002F110 mmHg\n   16. Uncorrected medical conditions, such as significant anemia, important electrolyte imbalance, and hyperthyroidism\n2. Acute decompensated heart failure NYHA class IV",{"count":528,"type":21},45,[24],"this study aims to investigate the effect of low vs high volume- high intensity interval training on functional capacity and quality of life in chronic heart failure patients",[28],"2026-01-03",{"date":534,"type":38},"2026-01-08",{"date":536,"type":21},"2025-12-10",{"date":538,"type":21},"2026-06-06",{"name":540,"class":76},"Cairo University",{"id":542,"slug":4,"hasResults":11,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":22,"phases":550,"briefSummary":551,"conditions":552,"keywords":553,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":77},"100614525","NCT07280728","Nurse-Led Education for Heart Failure Self-Care and Stability","Effectiveness of a Nurse-Led Face-to-Face Educational Intervention on Clinical Stability, Compliance, and Self-Care in Patients With Heart Failure Three Months After Hospital Discharge: An Open-Label Randomized Controlled Trial (EDUCATE Study)","EDUCATE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Hospital discharge from the Cardiology Unit of Lodi Hospital with a diagnosis of heart failure according to international guidelines\n* NYHA functional class II-IV assigned at discharge\n* First outpatient cardiology visit scheduled 30 (±15) days after hospital discharge\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Severe cognitive impairment (Six Item Screener score 0-3)\n* Admission from a unit other than the Cardiology Department of Lodi Hospital\n* NYHA class I\n* First cardiology visit scheduled \\\u003C30 or \\>45 days after discharge\n* Previous enrollment or follow-up in any Heart Failure Clinic\n* Acute coronary event within the previous 3 months",{"count":549,"type":21},118,[24],"Heart failure is a chronic condition that can lead to frequent hospitalizations and reduced quality of life. This study aims to evaluate whether a nurse-led, face-to-face educational intervention can improve clinical stability, treatment compliance, and self-care behaviors among patients with heart failure after hospital discharge. Participants will be randomly assigned to either the intervention group, receiving a structured 30-minute educational session using the teach-back method, or the control group, receiving standard follow-up care. The primary outcome is clinical stability at three months, assessed using the Heart Failure Somatic Perception Scale. Secondary outcomes include self-care and medication compliance measured up to 12 months. The study will be conducted at the ASST di Lodi Heart Failure Clinic in Italy and is expected to last three years.",[28],[27,554,555,556,557,558,559,560,561],"Self-Care","Patient Education","Nurse-Led Intervention","Teach-Back","Clinical Stability","Medication Adherence","Randomized Controlled Trial","Post-Discharge Care","2025-12-01",{"date":564,"type":38},"2025-12-12",{"date":566,"type":21},"2026-02-01",{"date":568,"type":21},"2029-02-01",{"name":570,"class":76},"Azienda Socio Sanitaria Territoriale di Lodi",{"id":572,"slug":4,"hasResults":11,"nctId":573,"briefTitle":574,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":11,"sex":17,"minAge":355,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":22,"phases":579,"briefSummary":580,"conditions":581,"keywords":583,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":77},"100437024","NCT04970888","Comparing the Effects of Combining Cognitive and Physical Exercise Training on Cognition, and Cerebral Blood Flow Regulation in Men and Women With Chronic Heart Failure","ReCARDIO","Inclusion Criteria:\n\n* Age ≥ 50 years old\n* Stable chronic HF on maximally tolerated background treatment for at least 2 months (stable therapy with ACE-I, ARBs and MRA for at least 2 months), regardless of LVEF\n* with no limitation of physical activity in ordinary physical activity (i.e. NYHA class I), moderate symptoms (i.e. NYHA class II) or marked limitation in activity (i.e. NYHA class III)\n* Able to perform cognitive and physical training.\n\nExclusion Criteria:\n\n* Acute cardiovascular event 1 month prior to randomization, including emergency visit or hospitalization for decompensated HF, acute myocardial infarction, stroke, and transient ischemic attack\n* Planned cardiovascular intervention within 6 months (implantation of any cardiac device, cardiac revascularization, heart transplantation)\n* Severe exercise intolerance\n* Contraindications for exercise testing (e.g., uncorrected severe aortic or carotid stenosis, severe pulmonary hypertension, severe non-revascularizable coronary disease including left main coronary stenosis, significant myocardial ischemia or arrhythmia during low-intensity exercise, acute HF)\n* Severe respiratory disease\n* Non-cardiopulmonary limitation to exercise (e.g., arthritis, claudication or any peripheral neurological disease including other neurodegenerative diseases such as disabling Parkinson)\n* Uncontrolled diabetes or untreated thyroid dysfunction\n* Current or recent malignancy with life expectancy \\\u003C 1 year\n* Chronic hemodialysis or peritoneal dialysis\n* Unable to read the informed consent form or unable to understand the oral explanations provided by the assessor.",{"count":578,"type":21},216,[24],"The objective of this project is to assess the effects of combined physical exercise and cognitive training interventions on cognitive and brain health in patients with heart failure (HF). Also, the role of sex on the effects of the interventions will be assessed.",[28,582],"Aging",[584,585,586,587,588,32,589,590,591],"cognition","physical exercise","cognitive training","brain functions","combined intervention","biomarkers","cerebral vasoreactivity","fitness","2025-11-24",{"date":594,"type":38},"2025-12-02",{"date":596,"type":38},"2021-09-01",{"date":598,"type":21},"2026-12-01",{"name":600,"class":76},"Montreal Heart Institute",{"id":602,"slug":4,"hasResults":11,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":606,"eligibilityCriteria":607,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":608,"targetDuration":4,"studyType":22,"phases":609,"briefSummary":610,"conditions":611,"keywords":614,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":77},"100536874","NCT06270498","Effect of Oral sucRosomIal Iron on exerciSE Capacity and Quality of Life in Patients With Heart Failure","Effect of Oral sucRosomIal Iron on exerciSE Capacity and Quality of Life in Patients With Heart Failure: a Randomized, Placebo-controlled Trial (RISE-HF)","RISE-HF","Inclusion Criteria:\n\n1. Chronic HF (New York Heart Association \\[NYHA\\] functional class II-IV) patients, on optimal therapy, and clinically stable for at least 4 weeks with no dose changes of HF drugs\n2. LVEF\\\u003C50% at screening visit (historical value can be used if performed within 6 months of screening visit)\n3. Either a documented hospitalization for HF in the previous 12 months of enrolment or an elevated NT-proBNP: ≥250 pg\u002FmL (or BNP ≥75 pg\u002FmL) for patients in normal sinus rhythm; ≥1,000 pg\u002FmL (or BNP ≥400 pg\u002FmL) for patients in atrial fibrillation\n4. TSAT \\\u003C20%\n5. Hemoglobin 10.0-16.0 g\u002FdL\n6. Rapid iron repletion with intravenous iron is not considered a clinical necessity by physicians after reviewing patient medical record (if anaemia is present, its grade is no more than mild)\n7. Age ≥18 years, male and female\n8. Willingness to provide informed consent\n9. Subjects who decide to use single or dual contraceptive methods to avoid conceiving during the study period\n\nExclusion Criteria:\n\n1. Neuromuscular, orthopedic or other non-cardiac condition that prevents the patient from exercise testing\n2. Exercise training program in the previous 3 months, or planned in the next 3 months\n3. Recent (\\\u003C3 month) acute coronary syndrome, coronary artery bypass surgery, percutaneous coronary interventions, transient ischemic attack, or stroke\n4. Severe valvular disease, hypertrophic obstructive cardiomyopathy, restrictive or constrictive cardiomyopathy, acute myocarditis\n5. Atrial fibrillation or flutter with a ventricular response rate of \\>100 beats per minute at rest\n6. Temperature ≤38 °C (oral or equivalent) or active infection as defined by current use of oral or intravenous antimicrobial agents\n7. Need for blood transfusion within the last month\n8. Hb\\\u003C10 g\u002FdL or Hb\\>16 g\u002FdL\n9. Rapid iron repletion with intravenous iron is considered a clinical necessity by physicians after reviewing patient medical record\n10. Documented active gastrointestinal bleeding\n11. Oral iron, i.v. iron or erythropoietin stimulating agent within the last 3 months\n12. eGFR ≤15 mL\u002Fmin or on hemodialysis\n13. Chronic liver disease and\u002For alanine transaminase or aspartate transaminase above 3 times the upper limit of the normal range\n14. Active cancer\n15. Evidence of iron overload (ferritin \\>400 ng\u002FmL)\n16. Hypersensitivity to any of the study products or known severe allergies\n17. Participation in another study\n18. Low body weight (≤35 kg)\n19. Known or anticipated pregnancy in the next 4 months\n20. Need for forbidden medications\n21. Breastfeeding\n22. Consumption of iron-rich foods or any food that alter iron absorption (i.e. food rich in vitamin C) due to dietary requirements\n23. Any pathological condition or disease associated with a reduction or an impairment of intestinal iron absorption (i.e., prior gastrectomy, atrophic gastritis, bariatric surgery, coeliac disease)",{"count":401,"type":21},[58],"The goal of this study is to investigate the effect of oral sucrosomial iron on exercise capacity and quality of life in patients with heart failure (HF) and iron deficiency (ID).\n\nThe main question the study aims to answer is whether oral sucrosomial iron improved exercise capacity, assessed by six-minute walk test, and quality of life, assessed by Kansas City Cardiomyopathy Questionnaire, compared with placebo.\n\nOne group of participants will receive treatment with oral sucrosomial iron and the other group will receive treatment with placebo.",[28,612,613],"Iron-deficiency","Left Ventricular Systolic Dysfunction",[32,64,615],"sucrosomial iron","2025-09-25",{"date":618,"type":38},"2025-10-01",{"date":620,"type":38},"2024-03-14",{"date":622,"type":21},"2026-06-14",{"name":624,"class":76},"Raffaele De Caterina",{"id":626,"slug":4,"hasResults":11,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":630,"eligibilityCriteria":631,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":632,"targetDuration":4,"studyType":22,"phases":633,"briefSummary":634,"conditions":635,"keywords":642,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":77},"100604453","NCT07149714","Temporary MCS With the iVAC 2L Transaortic Device in High-risk PCI","Temporary Mechanical Circulatory Support With the iVAC 2L Transaortic Device in High-risk Percutaneous Coronary Intervention","POTOK","Inclusion Criteria:\n\n* Multidisciplinary heart team consensus for high-risk PCI. HR-PCI was defined as any percutaneous intervention for coronary disease involving an unusually high risk of periprocedural circulatory collapse.\n* Signed Informed Consent to participate in the study\n\nExclusion Criteria:\n\n* Femoral artery diameter \\\u003C 6.0mm\n* Significant biventricular or right heart failure\n* Thrombus in the left ventricle\n* Presence of a mechanical aortic valve\n* Aortic valve stenosis\u002Fcalcification (equivalent to an orifice area of 0.6 cm2 or less) or moderate-to-severe aortic insufficiency (echocardiographic assessment graded as ≥+2)\n* Severe peripheral arterial disease precluding placement of the iVAC2L\n* Combined cardiorespiratory failure\n* Presence of an atrial or ventricular septal defect (including post infarct VSD)\n* Left ventricular rupture\n* Cardiac tamponade\n* Presence of any other subtype of shock\n* Known severe comorbidities independently affecting prognosis (chronic renal or liver failure, active malignancies etc.)\n* Recent major bleeding event (\\\u003C 3 months)\n* Recent stroke (\\\u003C 3 months)",{"count":56,"type":21},[24],"Patients with coronary artery disease and undergoing high-risk percutaneous coronary intervention (PCI) are at increased risk of hemodynamic instability and poor outcomes. Mechanical circulatory support (MCS) devices may offer hemodynamic stabilization during PCI, potentially improving short- and long-term outcomes. The study rationale is to investigate the safety and clinical efficacy of temporary MCS with the iVAC 2L transaortic device in high-risk percutaneous coronary intervention.\n\nThe transaortic system for short-term circulatory support with pulsatile blood flow iVAC 2L consists of an external membrane pump, a 17Fr diameter catheter for reversed blood flow (intake cannula) with a patented two-way rotary valve.\n\nThe pump has two chambers, one for blood and one for helium, separated by a flexible diaphragm. The blood chamber connects to the catheter and the air chamber connects to a standard IABP console. The bi-directional valve is located 72 mm from the aspiration tip of the catheter and determines the direction of blood flow. The catheter is advanced retrogradely through the common femoral artery so that the tip is located in the left ventricular (LV) cavity and the valve is in the ascending aorta. Synchronized with the cardiac cycle via ECG, the device draws blood from the LV into the pump chamber during systole and ejects blood from the pump into the ascending aorta during diastole.\n\nThe primary composite outcome is all-cause mortality, including acute myocardial infarction, stroke and TIA during hospitalization and at Day 360 of follow-up, expressed as a percentage of total patients.",[636,637,638,639,640,28,641],"Ischemic Cardiovascular Disease","Multivessel Coronary Artery Disease","Coronary Artery Disease","Cardiogenic Shock","Acute Heart Failure (AHF)","Percutaneous Coronary Intervention",[643,644,645],"Mechanical circulatory support","High-Risk Percutaneous Coronary Intervention","Coronary artery disease","2025-08-29",{"date":648,"type":38},"2025-09-08",{"date":650,"type":38},"2023-02-17",{"date":652,"type":21},"2029-02-17",{"name":264,"class":265},""]